新加坡医疗企业进入中国市场,前景不明

2019-05-08     1,848
新加坡医疗企业进入中国市场,前景不明

莱佛士重庆医院被视为一个大胆之举,透露出莱佛士急于向国外拓展市场,挽救业绩下滑的窘境。

由于中国的创业成本,新加坡最大的私人医疗集团——莱佛士医疗集团(RMG)2019年第一季度利润大幅下滑。重庆莱佛士医院被视为在中国医疗市场大胆创业的开始,为莱佛士提供无限扩展服务的机会。

新加坡医疗企业进入中国市场,前景不明

重庆莱佛士医院。

在可比较的基础上,若不计中国新医院的成本,该集团的利润将增长2.1%。在今年的展望中,莱佛士方面表示,预计将在2019年增加收入并保持盈利,“ 尽管重庆莱佛士医院预计会出现发展期亏损 ”。

A bold new venture into the Chinese healthcare market

First quarter profits have slumped at Raffles Medical Group (RMG), the largest private medical group practice in Singapore, thanks to startup costs in China. Raffles Hospital Chongqing is seen as the beginning of a bold new venture into the Chinese healthcare market for RMG providing unlimited opportunities to expand its services.

On a comparable basis, excluding the costs of the new hospital, the group’s profits would have grown by 2.1%. In its outlook for the year, the RMG said that it expected to grow its revenue and remain profitable in 2019, "notwithstanding the expected gestation loss for Raffles Hospital Chongqing".

转载请注明来源:狮城新闻